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Stefanie H. Meeuwis, MSc, Henriët van Middendorp, PhD, Gustavo Pacheco-Lopez, PhD,
Maarten K. Ninaber, MD, PhD, Adriana P.M. Lavrijsen, MD, PhD, Nic van der Wee, MD, PhD,
Dieuwke S. Veldhuijzen, PhD, and Andrea W.M. Evers, PhDABSTRACTObjective: Allergic rhinitis symptoms can be reduced by behaviorally conditioning antihistamine. It is unclear whether these findings
extend to histamine-induced itch or work when participants are informed about the conditioning procedure (open-label conditioning).
The current study aims to investigate the efficacy of (open-label) antipruritic behavioral conditioning for histamine-induced itch.
Methods: Healthy participants (n = 92; 84% female) were randomized to I) an open-label conditioned, II) closed-label conditioned, III)
conditioned-not-evoked control, or IV) nonconditioned control group. A two-phase conditioning paradigm was used. During acquisition,
a conditioned stimulus (CS; distinctively tasting beverage) was repeatedly paired with the H1-antihistamine levocetirizine (groups I–III).
During evocation, the CS was paired with placebo (I, II), or instead of the CS, water was paired with placebo (III). The nonconditioned
control group (IV) received CS with placebo in both phases. Itch after histamine iontophoresis and physiological data (i.e., spirometry,
heart rate, skin conductance) were assessed. Combined conditioned and combined control groups were first compared, and analyses were
repeated for separate groups.
Results: Marginally lower itch was reported in the combined conditioned compared with the control groups (F(1,88) = 2.10, p = .076,
η2partial = 0.02); no differences between separate groups were found. No effects on physiological data were found, except for heart rate,
which reduced significantly and consistently for control groups, and less consistently for conditioned groups (group by time interaction:
F(7,80) = 2.35, p = .031, η2partial = 0.17).
Conclusion: Limited support was found for the efficacy of antipruritic behavioral conditioning, regardless of whether participants were
informed about the conditioning procedure. The application of open-label conditioning in patient populations should be further researched.
Trial Registration: www.trialregister.nl; ID NTR5544.
Key words: placebo effects, behavioral conditioning, expectancy, histamine, itch, pruritus.ANCOVA = analysis of covariance, CS = conditioned stimulus,
FEV1 = forced expiratory volume in 1 second, FVC = forced vital
capacity, GLM = general linear model, HR = heart rate (in beats
per minute),NRS=Numeric Rating Scale, SCL= skin conductance
level, UCS = unconditioned stimulusINTRODUCTION
P lacebo effects are beneficial effects that cannot be attributed toactive treatment ingredients (1,2). Instead, these effects are
ascribed to expectancy mechanisms, with expectations of benefit
resulting in improvement of somatic symptoms (e.g., itch and
pain (3–6)). The opposite has also been demonstrated, with ex-
pectations of deterioration resulting in exacerbation of symptoms
or increased adverse effects (i.e., nocebo effects (3,7)). Current
evidence shows that placebo and nocebo effects can be induced
through multiple pathways, for example, by providing positive
or negative information regarding treatments, or through associa-
tive learning processes such as conditioning (8–10). In behavioral
conditioning, repeated pairing of an initially neutral stimulus (to-beSupplemental Content
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which elicits a certain innate response, may lead to the CS eliciting a
similar response (conditioned response), even when the UCS is not
presented (9,10).
There is evidence that conditioning of allergens to a CS can
exacerbate allergic symptoms, upregulate histamine release in
animal models of allergy (which has been linked to exacerbation
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ORIGINAL ARTICLEMoreover, studies indicate that conditioning can also potentially
alleviate allergic symptoms by repeatedly pairing a CS (e.g., a
novel-tasting beverage) with an H1-antihistamine (e.g., desloratadine)
as UCS (21,22). This has previously resulted in a conditioned ba-
sophil response to dust mite allergens (21). However, findings for
subjective symptoms were less clear, as these also tended to de-
crease in the control groups (21,22). Moreover, no study to date
has investigated whether conditioning of H1-antihistaminemay in-
fluence histamine-induced itch specifically. Because histamine is a
modulator of itch not only in allergic conditions but also in other
inflammatory conditions such as atopic dermatitis (23,24), demon-
strating these effects may provide a basis for new therapeutic ap-
proaches aimed at enhancement of placebo responses, reduction
of medication use, and minimization of adverse effects (25,26).
Traditionally, a blinded study protocol is used for behavioral
conditioning, in which participants do not know whether they re-
ceive medication or inert pills (27). This makes direct translation
of these effects to clinical practice difficult, as it insinuates that de-
ception is needed to elicit placebo effects, and patients in clinical
practice need to be fully informed about treatment (27). However,
there is accumulating evidence that placebo effects may also occur
when it is known that an inert substance is given (i.e., open-label).
Symptoms of allergic rhinitis, irritable bowel syndrome, and
chronic low back pain can be reduced when placebo pills are given
together with a rationale explaining the placebo effect (28–34).
The efficacy of open-label conditioning (i.e., explaining the learn-
ing procedure from the beginning) for reduction of symptoms such
as itch has not yet been demonstrated.
The current study investigated whether behavioral condi-
tioning of the antihistaminergic properties of levocetirizine
could reduce itch in response to a short-term histamine challenge.
Effects of behavioral conditioning on other clinical, physiological,
and psychological responses were explored. Moreover, the study
aimed to explore the effects of open- versus closed-label conditioning.MATERIALS AND METHODS
Study Design
Detailed methodology is described in the Methods section in the
Supplemental Material, Supplemental Digital Content 1, http://
links.lww.com/PSYMED/A581. This study was a block-random-
ized (1:1:1:1), placebo-controlled crossover study (Dutch Trial
Registry ID: NTR5544, registration on October 6, 2015) that
was approved by the Medical Ethical Committee at the Leiden
University Medical Center, the Netherlands (ID NL52687.058.15)
and conducted in concordance with the Declaration of Helsinki
(35). All participants provided written informed consent. Data for
the study were collected between October 2015 and October 2017.
Conditioning Paradigm and Blinding
In line with previous studies (21,22,36–39), a two-phase condi-
tioning paradigm was applied that consisted of an acquisition
phase, in which a distinctively tasting beverage (to-be CS) was
combined with a UCS (a capsule containing 5 mg levocetirizine
diHCl, an H1-antihistamine) or an identically looking placebo cap-
sule, and an evocation phase, in which the CS was combined with
a placebo capsule. Both phases had three sessions on three consec-
utive days, and were separated by a 4-day drug washout period.Psychosomatic Medicine, V 81 • 841-850 842Participants were allocated to I) an open-label conditioned group
(acquisition: CS + UCS with an explanation of conditioning and
its expected effects; evocation: CS + placebo); II) a closed-label
conditioned group (acquisition: CS+UCS; evocation: CS + placebo);
III) a conditioned-not-evoked control group (acquisition: CS + UCS;
evocation: water + placebo), which was added to control for carry-
over effects of the conditioning procedure; or IV) a nonconditioned
control group (acquisition: CS + placebo; evocation: CS + placebo),
which was added to control for the effects of CS only. Block ran-
domization was used to generate a randomization sequence and
was managed by an independent party (the Leiden University
Medical Center pharmacy that distributed the UCS and placebo
capsules). The study was conducted double blinded for the closed-
label conditioned group and nonconditioned control group, single
blinded for the conditioned-not-evoked group, and nonblinded for
the open-label conditioned group. In the conditioned-not-evoked
group, the CSwas not administered during evocation, and the acqui-
sition phase was conducted by a different experimenter in a different
laboratory setting (e.g., location and lighting), to prevent condi-
tioning to the environment. In the open-label conditioned group,
the experimenter provided participants with information regarding
the conditioning procedure at the start of acquisition (see the
Supplemental Material for further details, Supplemental Digital
Content 1, http://links.lww.com/PSYMED/A581). Notification of
allocation to these two groups by the pharmacy was given to the
experimenter after inclusion.
Participants
Healthymale and female volunteers aged between 18 and 35 years
were recruited for this study. Inclusion criteria consisted of a good
understanding of written and spoken Dutch, and absence of aller-
gic rhinitis or allergic conjunctivitis within 3 months before enroll-
ment in the study. Potential participants were excluded in case of
somatic or psychological morbidities that may interfere with the
study protocol or participants’ safety; allergic rhinitis or conjuncti-
vitis within 3 months before participation; any allergic condition
presenting symptoms other than rhinitis or conjunctivitis; recent
use of analgesics, antibiotics, antihistamines, or anti-inflammatory
medication; recent vaccinations; (intended) pregnancy; or intoler-
ance for any substances used in the study.
Procedure and Study Outcomes
An overview of the study protocol is provided in Figure 1. The
study took place at Leiden University and was advertised as a
study on the influence of psychological factors on antiallergic
medication. Participants were invited for a screening session, and
upon inclusion, psychological factors and expected itch were
assessed. Well-being was measured through questionnaires (mea-
surement set A; i.e., Positive and Negative Affect Schedule (40)),
State Trait Anxiety Index–State Anxiety (41)), and Numeric Rat-
ing Scales (NRS) for general well-being items). Next, spirometry
(forced vital capacity [FVC%predicted], forced expiratory volume
in 1 second [FEV1%predicted]) was assessed, and 5-minute measures
of heart rate (HR) and skin conductance level (SCL) were taken
(measurement set B). Itch was induced experimentally through
2.5 minutes of transdermal iontophoresis with a 0.6% diphosphate
histamine solution on the volar side of the nondominant forearm.
Itch was assessed verbally every 30 seconds during iontophoresis,November/December 2019
FIGURE 1. Overview of the study protocol. A conditioned stimulus (CS; distinctively tasting drink) was combined with an unconditioned
stimulus (UCS; levocetrizine) or placebo capsule (PLAC) during acquisition. During evocation, the CSwas combined with PLAC, and for
the conditioned-not-evoked group, PLACwas provided with water (H2O). Histamine iontophoresis (ITCH) was conducted at baseline and
in the final evocation session.
Conditioning Antihistamineand the self-rated and clinical skin response to histamine was mea-
sured (measurement set C). Finally, participants indicated how
much itch they expected to experience during the final evocation
session, and blood samples were taken to assess eosinophil profile
and immunoglobulin E response to aeroallergens. In the next
week, participants were invited for the acquisition sessions. For
each of the three acquisition sessions, measurement set A was
assessed before the CS was administered with the UCS or placebo
pill. After a 4-day drug washout, participants were invited for the
evocation sessions. During evocation, measurement sets A + B
were assessed pre-CS, and +30 and +60 minutes post-CS adminis-
tration, with an additional +90-minute post-CS assessment for the
final session. Measurement set C (histamine iontophoresis) was
reassessed in the final session between +60 and +90 minutes
post-CS. At the start of the final session, expected itch, remembered
itch, and expected medication efficacy were assessed. Finally, par-
ticipants filled in a closing questionnaire in which they indicated
whether they suspected to have received placebo or active medica-
tion, and compared the itch experienced during both tests. Partici-
pants rated the pleasantness of the CS taste in each session on an
NRS. Participation was reimbursed by €150. An overview of the
measurement schedule is provided in Figure 2.
Power Calculation and Statistical Analysis
A detailed description of the statistical analyses can be found in the
Methods section in the Supplemental Material, Supplemental
Digital Content 1, http://links.lww.com/PSYMED/A581. An a priori
power calculation using 1000 simulated data sets at a power level
of β = 0.85, an α level of α = .05, and an assumed effect size of
Δ/σ = 1/1 indicated that 92 participants were needed to find differ-
ences between the four groups. All analyses were performed usingPsychosomatic Medicine, V 81 • 841-850 843SPSS 23.0 for Windows (IBM SPSS Inc., Chicago, Illinois). As de-
scribed in the a priori plan for the statistical analyses, differences in
mean itch during iontophoresis in the evocation phase between the
combined open- and closed-label conditioned groups and the com-
bined control groups were assessed using a one-sided general linear
model (GLM) analysis of covariance (ANCOVA), including baseline
itch as covariate. Secondarily, a GLMANCOVAwas conducted two-
sided to explore effects between the separate groups. In case of signif-
icant group effects, Bonferroni post hoc tests were conducted. These
analyses were repeated for the secondary parameters itch expectation
and other iontophoresis-related outcomes (measurement set C). For
well-being and physiological outcomes (measurement sets A + B),
mixed between-within-subject repeated-measures analysis of variance
(RMAs) were conducted. In case of significant effects, within-subject
RMAs were conducted post hoc to assess changes from baseline
for individual groups. The groups were compared on the closing
questionnaire items by χ2 tests. Relations between suspected med-
ication intake and the primary outcome of itch were assessed by
GLM ANCOVAs. Because the open-label group received infor-
mation on medication administration, analyses for the closing
questionnaire items were repeated without this group. Assump-
tions were checked before analyses, and all analyses were con-
ducted with α = .05. As an effect size, η2partial was calculated for
each analysis. All values in theResults section representmean (stan-
dard deviation, or M [SD]), unless stated otherwise.
RESULTS
Participants
Ninety-nine participants were included in the study, of whom
seven dropped out of the study after inclusion for various reasons.November/December 2019
FIGURE 2. Overview of the measurement schedule. Numbers on the timeline are deducted fromCS administration, with −10 representing
pre-CS, and +30, +60, and +90 representing post-CS measurements. Personality questionnaires (Q); expected itch (EXP); measurement
sets for well-being (A); spirometry, heart rate, and skin conductance (B); and histamine iontophoresis (e.g., itch; C) and blood samples
(BL) were taken. Filler tasks consisted of neutral magazines, Sudokus, and puzzles.
ORIGINAL ARTICLEFor a complete overview of participants’ flow, see Supplemental
Figure 1, Supplemental Digital Content 1, http://links.lww.com/
PSYMED/A581. The final sample consisted of 92 participants
(Mage [SD], 22.1 [2.5] years; 84% female) randomized to the
open-label conditioned group (n = 23), the closed-label condi-
tioned group (n = 24), the conditioned-not-evoked control group
(n = 23), or the nonconditioned control group (n = 22). Partici-
pants did not differ significantly between groups on demographic
factors (see Table 1 [combined groups] and Supplemental Table 1
[separate groups], Supplemental Digital Content 1, http://links.
lww.com/PSYMED/A581).Group Differences at Baseline and During the
Acquisition Phase
Participants randomized to the combined open- and closed-label
conditioned groups showed a larger wheal area after baseline his-
tamine iontophoresis (M [SD], 12.3 [3.1]) compared with the com-
bined control groups (M [SD], 10.6 [3.6]; F(1,88) = 6.14, p = .015,
η2partial = 0.07). A marginal overall difference between the separate
groups was found for positive affect on the second acquisition day
(F(3,88) = 2.61, p = .057, η2partial = 0.08; Bonferroni post hoc tests:
p > .31). No other differences were found between groups at base-
line, or at the pre-CS measurements during the acquisition and
evocation sessions (all, p > .09). Groups did not differ in their rat-
ing of the pleasantness of the taste of the CS (all, p > .20), which
was generally rated as unpleasant (Mrating [SD], 3.8 [1.5]).Expected Itch
No differences in expected itch, remembered itch, or expected
medication efficacy were found between the combined condi-
tioned groups and the control groups (all, p > .11). When effects
of separate groups were explored, a medium-sized effect on ex-
pected itch was demonstrated (F(3,86) = 2.96, p = .037, η2par-
tial = 0.09), with post hoc Bonferroni tests illustrating that the
open-label conditioned group expected borderline significantly
less itch (M [SD], 3.2 [2.2]) compared with the conditioned-not-
evoked group (M [SD], 4.6 [1.6]; p = .050; Figure 3 and Supple-
mental Table 1, Supplemental Digital Content 1, http://links.lww.
com/PSYMED/A581).Psychosomatic Medicine, V 81 • 841-850 844Mean Self-reported Itch
As illustrated in Figure 4, a marginal small-sized conditioned
effect was demonstrated for mean itch (F(1,88) = 2.10, p = .076,
η2partial = 0.02), with the combined conditioned groups reporting
lower itch compared with the combined control groups in response
to iontophoresis during evocation (Mdifference, −0.34; standard error,
0.24). A nonsignificant difference in itch was found when analyses
were repeated for the separate groups (F(3,86) = 1.47, p = .23,
η2partial = 0.05).
Self-rated and Clinical Skin Response to Histamine
Iontophoresis
No effects on self-rated skin response to iontophoresis were dem-
onstrated for both the combined (F(1,88) = 0.47, p = .25, η2par-
tial = 0.01) and separate group analyses (F(3,86) = 0.53, p = .66,
η2partial = 0.02). Moreover, no effects were detected for the clinical
skin response parameters (all, p > .21; see also Table 1 [combined
groups] and Supplemental Table 1 [separate groups], Supplemen-
tal Digital Content 1, http://links.lww.com/PSYMED/A581).
Spirometry
No significant group by time interactions were found for
FVC%predicted or FEV1%predicted during the course of the evocation
sessions for both the combined and separate group analyses (all,
p > .32), indicating that conditioning did not evoke changes in
spirometry over time. In addition, no main effect of group on spi-
rometry parameters was found (all, p > .13; Supplemental Tables
2 and 3, Supplemental Digital Content 1, http://links.lww.com/
PSYMED/A581).
HR and SCL
Amedium-sized significant group by time interaction was dem-
onstrated in the combined groups for HR (Wilk λ = 0.83,
F(7,80) = 2.35, p = .031, η2partial = 0.17). Separate-group RMAs
demonstrated an overall reduction in HR compared with baseline
for both conditioned and control groups (both, Wilk λ > 0.25;
both, p < .001). Post hoc comparisons over time demonstrated that
in the combined conditioned groups, HR was significantly reduced
compared with baseline for only three of seven post-CS measures
(p ≤ .001). In the combined control groups, HR was significantlyNovember/December 2019
TABLE 1. Means, SDs and Analyses of (Co)Variance Results for the Combined Conditioned Groups Versus the Combined
Control Groups
ANCOVA Results:








Control Groups (n = 45) p η2partial
Demographic factors
Agea, M (SD) 22.59 (3.00) 21.44 (1.80) .15
Body mass indexb, M (SD) 23.53 (3.29) 22.90 (3.35) .37
Sex (male), n (%) 9 (19.6) 6 (13.3) .42
Ethnicity (white), n (%)c 41 (93.2) 41 (95.3) .51
Allergy, anamnesis (yes), n (%) 14 (30.4) 14 (31.1) .94
Allergy, IgE response (positive), n (%)d 16 (34.8) 18 (41.9) .49
Eosinophilic profile (within reference range), n (%) 45 (97.8) 42 (93.3) .39
History of antihistamine usee 12 (26.1) 8 (17.8) .34
Preconditioning histamine iontophoresis (baseline), M (SD)
Process measure
Expected itch before iontophoresis 4.27 (2.06) 4.17 (2.04) .83 <0.01
Expected itch after iontophoresis 3.79 (1.87) 3.92 (1.93) .75 <0.01
Primary outcome measure
Mean self-reported itch 3.66 (1.94) 3.39 (1.66) .48 <0.01
Secondary outcome measures
Subjective skin response 24.19 (14.22) 24.62 (11.79) .88 <0.01
Wheal area (cm2)f 12.33 (3.05) 10.63 (3.55) .02 0.07
Flare area (cm2)f 47.98 (12.46) 46.90 (10.63) .66 <0.01
Skin temperature change (°C)g 1.66 (1.57) 1.64 (1.83) .96 <0.01
Postconditioning histamine iontophoresis (evocation)
Process measure
Expected itchh 3.79 (2.25) 4.25 (1.71) .15 0.02
Remembered itch from baseline 3.96 (2.12) 3.90 (1.99) .90 <0.01
Expected medication efficacy 4.60 (2.33) 3.81 (2.40) .11 0.03
Primary outcome measure
Mean self-reported itchh 2.88 (1.96) 3.02 (1.54) .08 0.02
Secondary outcome measures
Subjective skin responseh 23.81 (14.28) 25.39 (11.37) .50 <0.01
Wheal area (cm2)i 11.03 (3.09) 10.00 (3.41) .66 <0.01
Flare area (cm2)i 45.29 (12.82) 45.31 (12.18) .45 <0.01
Skin temperature change (°C)g 1.33 (1.71) 1.06 (1.47) .42 <0.01
ANCOVA = analysis of covariance; M (SD) = mean (standard deviation); IgE = Immunoglobulin E.
a As tested by nonparametric Mann-Whitney test (analysis of variance assumptions were violated).
b n = 1 missing.
c n = 4 missing.
d n = 1 missing.
e Not within the past 2 months and an extensive history of levocetirizine use was considered ground for exclusion.
f Analysis corrected for the amount of time passed between histamine iontophoresis and measurement of the variable.
g Calculated as posthistamine iontophoresis skin temperature (control).
h Analysis corrected for preconditioning (baseline) variable.
i Analysis corrected for preconditioning (baseline) variable, as well as for the amount of time passed between histamine iontophoresis and measurement of the variable.
Conditioning Antihistamine
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FIGURE 3. Means and standard errors of expected itch, with (A) the effects of the combined conditioned groups and the combined control
groups on expected itch, controlled for baseline expected itch as measured postiontophoresis during the screening, and (B) the effects of the
separate groups on expected itch.
ORIGINAL ARTICLEreduced compared with baseline for six of seven post-CS measures
(p ≤ .001) andmarginally reduced for the other (1/7) post-CSmeasure
(p = .075). When analyses were repeated for the four (noncombined)
groups, a similar medium-sized group by time interaction was found
(Wilk λ = 0.64, F(21,225) = 1.79, p = .021, η2partial = 0.14). Post hoc
separate-group RMAs and pairwise comparisons demonstrated
significant HR reduction in line with the patterns for the combined
groups. No group by time interactions (both, p > .44) or main ef-
fects of group (both, p > .43) were found for SCL in analyses with
combined or separate groups. An overview is provided in Supple-
mental Tables 2 and 3, Supplemental Digital Content 1, http://
links.lww.com/PSYMED/A581.Well-being
No group by time interactions (all, p > .23) or main effects of
group (all, p > .11) were demonstrated for the Positive and Nega-
tive Affect Schedule positive affect, State Trait Anxiety Index–
State Anxiety, or NRS general well-being measures for both the
combined and separate group analyses (see Supplemental TablePsychosomatic Medicine, V 81 • 841-850 8462 and 3, Supplemental Digital Content 1, http://links.lww.com/
PSYMED/A581).
Closing Questionnaire: Suspected Medication Intake
and Its Association With Mean Itch and Other
Iontophoresis-Related Outcomes
No differences between groups were found when participants
compared baseline and evocation itch in the closing questionnaire
(all, p > .15). The groups differed marginally to significantly in
suspected medication intake for all sessions (all, p < .066), except
for the first evocation session. When the open-label conditioned
group was excluded from the analysis, no differences were found
(all, p > .11). Participants who suspected taking active medication
during the final evocation session had reported less itch during
iontophoresis as compared with those who suspected taking
placebo (open-label conditioned group included: F(1,88) = 3.82,
p = .054, η2partial = 0.04; open-label conditioned group excluded:
F(1,65) = 6.09, p = .016, η2partial = 0.09) and also reported lower
subjective skin response (open-label conditioned group included:
F(1,88) = 5.95, p = .017, η2partial = 0.06; open-label conditionedNovember/December 2019
FIGURE 4. Means and standard errors of the mean for itch during iontophoresis in the final evocation session, with (A) mean itch for the
combined conditioned and the combined control groups, and (B) mean itch for the separate groups.
Conditioning Antihistaminegroup excluded: F(1,65) = 4.92, p = .030, η2partial = 0.07; Supple-
mental Tables 4 and 5, Supplemental Digital Content 1, http://
links.lww.com/PSYMED/A581).
DISCUSSION
The current study investigated whether behavioral conditioning of
the antihistaminergic properties of levocetirizine could reduce itch
and other clinical, physiological, and psychological responses to
histamine, under both open-label (i.e., with participants knowing
about the conditioning procedure) and closed-label conditions.
Conditioning was found to bemarginally effective in reducing itch
when the combined conditioned groups were compared with the
combined control groups. However, no effects of conditioning
were found for self-rated or clinical skin responses to histamine.
Marginal antipruritic effects occurred regardless of whether partic-
ipants were informed about the procedure, implying that, if further
optimized, open-label behavioral conditioning might be suitable
for future applications in clinical practice.
These findings show that conditioning, albeit only marginally,
influenced self-reported itch, which is in line with previous find-
ings that show that associative learning mechanisms can influence
itch and allergic symptoms (11,14,21,22). Most studies havePsychosomatic Medicine, V 81 • 841-850 847investigated conditioned exacerbation of allergic responses,
whereas evidence for alleviation of itch through associative learn-
ingmechanisms is more limited and has only so far been examined
in allergic patients (21,22). In patients, it may be especially diffi-
cult to ascribe findings exclusively to behavioral conditioning be-
cause external influences on learning may also be relevant. For
example, natural fluctuations in symptom severity during acquisi-
tion of the conditioned response may affect conscious expectancy,
due to these fluctuations being interpreted as medication effects.
This in turn could influence symptom reporting within both the
conditioned and control groups. Resultantly, to reduce the influ-
ence of such external factors on conditioning, the current study
sought to investigate whether antipruritic effects could be condi-
tioned in healthy volunteers.
Goebel and colleagues (21) had previously found a unique con-
ditioned response for basophil activation in allergic patients, but
symptoms reduced regardless of group allocation. Vits and col-
leagues (22) confirmed these findings and demonstrated symptom
reduction for the conditioned and sham-conditioned (placebo) pa-
tient groups, compared with a natural history group. This led them
to conclude that other cognitive processes, for example, patients’
expectations of benefit, may be relevant. Likewise, the currentNovember/December 2019
ORIGINAL ARTICLEstudy provides only limited evidence for the role of conditioning in
reducing histamine-induced itch. Some differences between the
current study and previous studies can be noted. In the studies of
Goebel and colleagues (21) and Vits and colleagues (22), patients
reported symptoms at the time of enrollment in the study. In the
current study, the sample consisted of nonallergic participants, or
allergic participants who had not experienced symptoms for
some time before enrollment. Potentially, this may have elicited
smaller conditioned responses, as the pharmacological effects
of levocetirizine during acquisition may not have been clearly
perceived as much as they would be when allergic symptoms
were present. Moreover, itch was induced in the final evocation
session, to prevent that histamine iontophoresis—which entails
the introduction of a foreign chemical substance to the skin
(42)—interfered with measurements of conditioned responses
for other study outcomes. Although literature indicates that
conditioned immunological responses can persist for multiple—
potentially even up to 14—evocation moments (39,43,44), it
may be possible that some extinction in the conditioned response
was already present in the second and third evocation sessions.
Future research could investigate whether conditioned effects
for itch are stronger at earlier evocation moments, for example,
when participants are for the first time reexposed to the CS after
the acquisition phase. Alternatively, it may be possible that the
antipruritic effects of levocetirizine were too small for experimen-
tal histamine-induced itch to be effectively conditioned. Indeed, in
the current study, itch reduced from baseline in general, with only
marginal differences between the conditioned and control groups
(21.3% reduction of itch from baseline in the conditioned groups
versus 10.9% reduction in the control groups). Previous evidence
dispels the notion that this small difference between groups may
be due to failure of the UCS to suppress itch though, because it
is demonstrated that levocetirizine has a suppression rate for itch
that lies between 62% and 94% (45–47). A similar suppression
rate would be expected for levocetirizine in the current study.
Future research, however, may want to include a drug control
group to confirm this notion and to be able to directly compare
conditioned with nonconditioned responses.
Speculatively, the marginal antipruritic conditioned effect in
the current study could have emerged through peripheral neurobi-
ological mechanisms, for example, immune-mediated inhibition
of pruriceptor neurons (48–50). Such mechanisms have been
proposed to underlie systemic behaviorally conditioned immu-
nosuppression (8,51). Alternatively, effects may have emerged
through top-down central nervous system antipruritic mecha-
nisms, for example, in case of itch with a neuropathic and psy-
chogenic origin (23,52,53). As an example of central nervous
system–mediated itch, itch has been found to be socially conta-
gious in both patients and healthy volunteers (54–56). Future re-
search may aim to clarify through which pathways antipruritic
conditioned effects are established.
No conditioning effects were found for spirometry parameters.
Literature indicates that pulmonary conditions such as asthma are
sensitive to placebo responding (57,58), and antihistamines have
been found to have bronchodilatory properties, as shown by their
impact on spirometry parameters such as FEV1 (59–62). As such,
we explored whether conditioning of antihistamines could affect
these parameters as well. The missing data rate in the current study
likely affected the findings, however, and the study may have beenPsychosomatic Medicine, V 81 • 841-850 848underpowered for small effects. Moreover, as the sample consisted
of healthy volunteers, conditioned responses may be very small
because lung function may have already been optimal for a large
number of participants. It may be interesting for future research
to test the effects of conditioning with antihistamines by experi-
mentally inducing bronchoconstriction, for example, through em-
bedding a histamine bronchial provocation test. No conditioned
responses were found for the secondary parameter SCL. HR re-
duced significantly during evocation for the combined control
groups. The time that participants spent sitting in the laboratory
was relatively inactive, which likely explains the decrease in HR.
For the conditioned groups, HR did not decrease as much in the
second and final evocation sessions. Levocetirizine is considered
safe for use, and studies show no effects on cardiac safety param-
eters (63); however, subclinical cardiac effects are often not re-
ported. Moreover, H1-antihistamines—including cetirizine, from
which levocetirizine is derived—have been associated with tachy-
cardia and other cardiac adverse effects (64–66). As such, the dif-
ference in HR change over time between the conditioned and
control groups might speculatively be the result of a conditioned
response, although this should be further investigated. In addition,
future researchmay aim to investigate how to enhance the learning
process exclusively for the itch-suppressive effects of antihista-
mines, while avoiding conditioning of adverse effects.
Following the open-label rationale, significantly lower itch was
expected during evocation in the open-label group compared with
the conditioned-not-evoked group. However, although findings
were in the expected direction, itch expectations in the open-label
group did not significantly differ from those in the closed-label
conditioned and nonconditioned groups. That an open-label ratio-
nale may potentially influence expectancy is in line with studies
that found that inert pills combined with an open-label rationale
can reliably induce placebo effects (28–34). It has also been shown
that an open-label rationale regarding the role of expectations in
eliciting placebo effects for itch can, in an experimental setting, re-
sult in lower expected itch even without providing inert pills (67).
The current study extends these findings by preliminary showing
an effect of an open-label rationale for a conditioning framework.
Potentially, these expectations may help strengthen placebo effects
induced by conditioning, although this needs to be investigated
more extensively. Demonstrating the efficacy of open-label condi-
tioning could lead toward new therapeutic possibilities and help
facilitate utilization of placebo effect mechanisms in clinical prac-
tice. It should be noted, though, that the open-label rationale in the
current study consisted of multiple components (e.g., an explana-
tion of the conditioning procedure, a suggestion that effects may
be as large as the effects of the medication, and a suggestion of re-
duced itch). Future research may clarify which of these compo-
nents are essential for inducing expectations of reduced itch, and
investigate what other factors help optimize these effects. For ex-
ample, higher likability and competence of a health care provider
have been shown to enhance placebo effects for allergic responses
(68). It may be worthwhile to investigate to which extent factors
such as likability and competence may influence the efficacy of
an open-label rationale as well.
Some limitations of the current study should be considered.
Because participants were mostly women, a sex bias cannot be ex-
cluded. The experimenter was blinded to group allocation only for
the closed-label conditioned and the nonconditioned groups, butNovember/December 2019
Conditioning Antihistaminenot for the open-label conditioned and conditioned-not-evoked
groups, because of the differences in the protocol for these latter
two groups. Future research may consider having a second, blinded
experimenter performing measurements, to prevent that the experi-
menters’ own expectations influence measurement of the outcome
parameters. Second, participants underwent histamine iontophoresis
only twice, to prevent interference of histamine application on the
conditioned response. As a result, it was not possible to assess con-
ditioned effects for itch on the first and second evocation days, or to
assesswhether extinctionmay have taken place. In addition, no drug
control groupwas included in the current study.Moreover, effects of
antihistamine administration were not assessed in the acquisition
phase because this could influence participants’ conscious ex-
pectancy and thus the conditioning procedure. Because the effi-
cacy of levocetirizine for inhibiting the response to histamine
has been described in previous literature (45–47,63), we did
not directly compare the magnitude of conditioned effects with
those of levocetirizine. Future research may consider measuring
the response to histamine on multiple testing days and including
a drug control group. Finally, all groups received some form of
intervention (either conditioning or placebo throughout the study).
This may complicate an estimation of a true placebo response, as
the idea of receiving an intervention may already influence study
outcomes. Moreover, itch was induced twice. Although unlikely
to have largely affected study findings—given that the itch stimulus
was of short duration and inductions were spaced over 2 weeks
apart—habituation cannot be ruled out. Future research may also
consider adding a natural history group to control for this.
In conclusion, the current study provides preliminary support
for behavioral conditioning of antipruritic effects. In addition, the
findings suggest that conditioning may be effective when it is
known that a learning paradigm is used. Future research may
aim to clarify under which circumstances and on which evocation
moments conditioning can be successful in reducing itch. Demon-
strating the efficacy of (open-label) conditioning of antipruritic
effects may lead toward new therapeutic possibilities. Moreover,
further investigation of the content of the open-label rationale
may help facilitate utilization of placebo effect mechanisms in
clinical practice.
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